Drugs & Targets Bizengri gets FDA approval for bile cancer, becomes seventh drug approved under the priority voucher program May 15, 2026Vol.52 No.19
Drugs & Targets FDA clears AI digital pathology risk stratification tool in breast cancer May 15, 2026Vol.52 No.19
Drugs & Targets FDA permits expanded access for investigational pancreatic cancer drug daraxonrasib May 08, 2026Vol.52 No.18By Claire Marie Porter
Drugs & Targets FDA approves Jakafi XR tablets for myelofibrosis, polycythemia vera, and graft-versus-host disease May 08, 2026Vol.52 No.18
Drugs & Targets ODAC recommends against approval of camizestrant NDA, gives a nod to sNDA for capivasertib May 01, 2026Vol.52 No.17By Jacquelyn Cobb
Drugs & Targets FDA grants priority review for Ziihera in first-line HER2+ GEA May 01, 2026Vol.52 No.17
Drugs & Targets FDA approval of IDE supplement to expand Alpha DaRT IMPACT Trial to patients with pancreatic cancer receiving gemcitabine with abraxane May 01, 2026Vol.52 No.17
Drugs & Targets Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule May 01, 2026Vol.52 No.17
